Clearstead Advisors’s Anavex Life Sciences AVXL Stock Holding History

Clearstead Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247	Buy	+95	New	+$281	﹤0.01%	3132
2026 Q1	–	Sell	-481	Closed	-$1.71K	–	2305
2025 Q4	$1.71K	Hold	481	–	–	﹤0.01%	2158
2025 Q3	$4.28K	Hold	481	–	–	﹤0.01%	2214
2025 Q2	$4.43K	Hold	481	–	–	﹤0.01%	2142
2025 Q1	$4.13K	Hold	481	–	–	﹤0.01%	1782
2024 Q4	$5.17K	Hold	481	–	–	﹤0.01%	1714
2024 Q3	$2.73K	Hold	481	–	–	﹤0.01%	1806
2024 Q2	$2.03K	Hold	481	–	–	﹤0.01%	1815
2024 Q1	$1.92K	Hold	481	–	–	﹤0.01%	1320
2023 Q4	$4.48K	Hold	481	–	–	﹤0.01%	1176
2023 Q3	$3.15K	Hold	481	–	–	﹤0.01%	1153
2023 Q2	$3.91K	Hold	481	–	–	﹤0.01%	1073
2023 Q1	$4.12K	Hold	481	–	–	﹤0.01%	1041
2022 Q4	$4.45K	Hold	481	–	–	﹤0.01%	998
2022 Q3	$5K	Hold	481	–	–	﹤0.01%	968
2022 Q2	$5K	Hold	481	–	–	﹤0.01%	994
2022 Q1	$6K	Hold	481	–	–	﹤0.01%	1050
2021 Q4	$8K	Hold	481	–	–	﹤0.01%	944
2021 Q3	$9K	Hold	481	–	–	﹤0.01%	954
2021 Q2	$11K	Hold	481	–	–	﹤0.01%	784
2021 Q1	$7K	Buy	+481	New	+$5.25K	﹤0.01%	824

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Advisors's AVXL Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 95 shares worth $247. The stake represents ﹤0.01% of the portfolio and ranks #3132 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in AVXL as recently as Q4 2025.

Clearstead Advisors first reported a position in AVXL in Q1 2021 and has held it in 21 quarters since. The position peaked at $11K in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Clearstead Advisors held 95 shares of Anavex Life Sciences worth $247 as of Q2 2026.
Anavex Life Sciences was a new Clearstead Advisors position in Q2 2026.
Anavex Life Sciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3132 holding.
Clearstead Advisors first reported a position in Anavex Life Sciences in Q1 2021 and has held it in 21 quarters since.
Clearstead Advisors's Anavex Life Sciences position peaked at $11K in Q2 2021.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.